Cited by 77Liver Disease Diagnosis and TreatmentClinical Laboratory Practices and Quality ControlAlcohol Consumption and Health Effects

Definition of healthy ranges for alanine aminotransferase levels: a 2021 update

Open access
Valenti, Luca, Pelusi, Serena, Bianco, Cristiana, Ceriotti, Ferruccio, Berzuini, Alessandra, Iogna Prat, Laura, Trotti, Roberta, Malvestiti, Francesco +7 more·2021·Hepatology Communications

Abstract

The changing epidemiology of liver disease, and modifications in the recommended analytical methodology call for a re-evaluation of the upper reference limits (URLs) of alanine aminotransferase (ALT) levels. Using the same approach consolidated 20 years ago to define the healthy population, we defined the URL for the newly recommended International Federation of Clinical Chemistry (IFCC) standardized test. In a cross-sectional study, we examined 21,296 apparently healthy blood donors (age 18-65 years) and calculated the sex-specific URL by the 95th percentile in individuals without risk factors for liver disease. These were tested for the ability to predict liver damage in a subset of 745 participants with dysmetabolism, in an independent cohort of 977 unselected donors, and in 899 patients with chronic liver disease. ALT levels were measured by the IFCC test. Male sex, body mass index, glucose, lipids, ferritin, hypertension, and younger age were independent ALT predictors (P < 0.001). Updated URLs were identified at 42/30 U/L in males/females, approximately 30% lower than those currently recommended by the IFCC. Due to improved sensitivity, they conferred the ability to detect steatosis and significant fibrosis in individuals with dysmetabolism (odds ratio [OR] = 2.31, range 1.40-3.80, P = 0.001; and OR = 3.35, range 1.19-9.42, P = 0.021; respectively), although with a limited accuracy, and significant fibrosis in unselected donors (OR = 2.32, 1.02-5.31, P = 0.045). Updated URLs had a moderate to high accuracy to discriminate liver conditions (area under the receiver operating characteristic curve = 0.81, range 0.78-0.91). Conclusion: Updated URLs by the IFCC method were lower than those calculated in initial studies, but higher than those in use with the recommended old, nonstandardized method, and were able to better predict liver disease. The limited awareness that different techniques are still in use should be regarded as a possible source of medical errors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1794

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevation of liver enzymes, namely aminotransferases, is associated with increased liver-related mortality.

    “Elevation of liver enzymes, namely aminotransferases, is associated with increased liver-related mortality.”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [20]

    The opening passage (listed under Abstract; page unavailable) states that elevated ALT predicts mortality in the general population, independent of liver disease. It does not identify that mortality as liver-related. The Results associate elevated ALT with steatosis and fibrosis, but do not report liver-related deaths; the claim also broadens ALT to aminotransferases generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 41 · Cited by 77

Authors
Valenti, L., Pelusi, S., Bianco, C., Ceriotti, F., Berzuini, A., Iogna Prat, L., Trotti, R., Malvestiti, F., D’Ambrosio, R., Lampertico, P., Colli, A., Colombo, M., Tsochatzis, E. A., Fraquelli, M., & Prati, D.
Affiliations
  • University of Milan (IT)
  • University of Udine (IT)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
  • UCL Institute for Liver and Digestive Health,Royal Free Hospital and UCL,London,United Kingdom
  • IRCCS Ospedale San Raffaele (IT)
  • The Royal Free Hospital (GB)
Corresponding author
Prati, Daniele
Venue
Hepatology Communications
Published
2021-09-14
Volume
5
Issue
11
Pages
1824-1832
ISSN
2471-254X (ISSN-L)
OpenAlex
W3201561713
Cited by
77
References
41
Citations by year
2026: 7 · 2025: 15 · 2024: 23 · 2023: 19 · 2022: 11 · 2021: 2
FWCI
9.90
Type
journal article
Language
en
Open access
Locations
  • Hepatology Communications (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministero della Salute (101016726, PR-0361, RF- 2016-02364358, 777377)
  • Associazione Italiana per la Ricerca sul Cancro (16888, RF-2016-02364358)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (“Liver Bible” PR‐0361)
  • Grifols
  • Horizon 2020 Framework Programme (101016726 REVEAL, 777377 LITMUS)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
alanine aminotransferase, upper reference limit, liver disease, chronic liver disease, hepatic steatosis, liver fibrosis, dysmetabolism, blood donors, sex-specific reference values, analytical method comparison, diagnostic accuracy
MeSH terms
Adolescent, Adult, Age Factors, Aged, Alanine Transaminase, Blood Donors, Cross-Sectional Studies, Female, Humans, Liver Diseases, Male, Middle Aged, Reference Values, ROC Curve, Sex Factors, Body Mass Index, Odds Ratio, Young Adult, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review